Omalizumab inhibits allergen challenge-induced nasal response

European Respiratory Journal

Volumn 23, Issue 3, 2004, Pages 414-418

  Hanf, Gerald ^a   Noga, O ^a   O'Connor, A ^a   Kunkel, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Allergic rhinitis; Anti imunoglobulin E; Omalizumab; rhuMAb E25

Indexed keywords

HISTAMINE; HOUSE DUST ALLERGEN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN E; OMALIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC REACTION; ALLERGIC RHINITIS; ARTICLE; BIRCH; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DANDER; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GRASS; HISTAMINE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; MALE; NOSE MUCUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SCORING SYSTEM; SYMPTOMATOLOGY; WILCOXON SIGNED RANKS TEST;

ADULT; ALLERGENS; ANTIBODIES, MONOCLONAL; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE; HUMANS; IMMUNOGLOBULIN E; MALE; NASAL LAVAGE FLUID; NASAL PROVOCATION TESTS; RHINITIS, ALLERGIC, PERENNIAL; SERUM ALBUMIN;

EID: 1542609297     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00024504     Document Type: Article

References (23)

1. Lundback B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998; 28: Suppl. 2, 3-10.
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351: 1225-1232.
3. Ishizaka T, Ishizaka K. Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984; 34: 188-235.
4. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308-312.
5. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-2632.
6. Saban R, Haak Frendscho M, Zine M, et al. Human FcεRI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994; 94: 836-843.
7. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-259.
8. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110-121.
9. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279: 1000-1008.
10. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341: 1966-1973.
11. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-1834.
12. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-1840.
13. Barnes PJ. Anti-IgE antibody therapy for asthma. N Engl J Med 1999; 341: 2006-2008.
14. Solèr M, Matz J, Townley R, et al. The Anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-261.
15. Naclerio RM, Meier HL, Kagey Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128: 597-602.
16. Siraganian RP. Automated histamine release. A method for in vitro allergy diagnosis. Int Arch Allergy Appl Immunol 1975; 49: 108-110.
17. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 1992; 90: 699-704.
18. Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FcεRI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162: 5624-5630.
19. Plaut M, Pierce JH, Watson CJ, Hanley Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores. Nature 1989; 339: 64-67.
20. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990; 346: 274-276.
21. Burd PR, Rogers HW, Gordon JR, et al. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med 1989; 170: 245-257.
22. Dinalrello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153-176.
23. Bachert C, Wagenmann M, Hauser U. Proinflammatory cytokines: measurement in nasal secretion and induction of adhesion receptor expression. Int Arch Allergy Immunol 1995; 107: 106-108.